With approval, the HeartMate 3 System offers physicians in Europe the most advanced ventricular assist technology available to support the management of patients with advanced stage heart failure ST.
Abbott Laboratories, Inc. ABT recently announced that the FDA has approved a change of label for its HeartMate 3 left ventricular assist device (LVAD or heart pump). The development, meant exclusively ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
New data from the ARIES trial show for the first time that an aspirin-free regimen can improve outcomes for people living with the heart pump by reducing hospitalizations without increasing the risk ...
BOSTON, MA—The best mean arterial pressure (MAP) range in the first several months after implantation of the HeartMate 3 left ventricular assist device (LVAD) appears to be 85 to 100 mm Hg, according ...
Lifesaving therapy offers hope for patients with advanced heart failure, serving as a bridge to heart transplantation or long-term therapy. WASHINGTON, Nov. 17, 2025 /PRNewswire/ -- MedStar Washington ...
An FDA alert warned of problems with some Mobile Power Units of the HeartMate II and HeartMate 3 left ventricular assist devices. Medtronic's thin OmniaSecure defibrillation lead got FDA approval for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results